Lewy body diseases (LBD), consisting of Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB), are characterized by progressive degeneration in dopaminergic and acetylcholine neurons, as well as abnormal accumulation of Lewy bodies and Lewy neurites.
The shared clinical features of PDD and DLB include progressive cognitive impairment associated with parkinsonism, visual hallucinations, rapid eye movement sleep behavior disorder and fluctuations in alertness and cognition. Concomitant Alzheimer’s disease co-pathology is common in the PDD and DLB, which comprise a leading cause of dementia and economic burden. Uncovering the mechanism of α-synuclein in Lewy body diseases and its interplay with tau and amyloid-β plaque pathology will be key to identifying disease-specific targets for disease discovery and therapeutic development. In addition, imaging and biofluid biomarkers are needed to improve diagnosis and better track Lewy body disease progression.
This research topic aims to gather further insight into the most recent advances in Lewy body diseases and to generate a multidimensional discussion on the early detection, assessment, diagnosis, prognosis, and management of patients with Lewy body diseases.
We welcome original articles and reviews addressing the following:
- Application of neuroimaging techniques in Lewy body diseases
- Biomarkers from blood, saliva, urine, skin tissue or CSF in Lewy body diseases
- Similarities and differences between Parkinson’s disease with dementia and dementia with Lewy bodies
- Innovative methodology to differentiate Lewy body diseases from other movement disorders
- Novel classification method on subtypes of LBD by clinical phenotypes, genetic variations, and others
- Basic research about α-synuclein as well as its synergistic effect of tau and amyloid-β underlying the mechanism in Lewy body diseases
Lewy body diseases (LBD), consisting of Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB), are characterized by progressive degeneration in dopaminergic and acetylcholine neurons, as well as abnormal accumulation of Lewy bodies and Lewy neurites.
The shared clinical features of PDD and DLB include progressive cognitive impairment associated with parkinsonism, visual hallucinations, rapid eye movement sleep behavior disorder and fluctuations in alertness and cognition. Concomitant Alzheimer’s disease co-pathology is common in the PDD and DLB, which comprise a leading cause of dementia and economic burden. Uncovering the mechanism of α-synuclein in Lewy body diseases and its interplay with tau and amyloid-β plaque pathology will be key to identifying disease-specific targets for disease discovery and therapeutic development. In addition, imaging and biofluid biomarkers are needed to improve diagnosis and better track Lewy body disease progression.
This research topic aims to gather further insight into the most recent advances in Lewy body diseases and to generate a multidimensional discussion on the early detection, assessment, diagnosis, prognosis, and management of patients with Lewy body diseases.
We welcome original articles and reviews addressing the following:
- Application of neuroimaging techniques in Lewy body diseases
- Biomarkers from blood, saliva, urine, skin tissue or CSF in Lewy body diseases
- Similarities and differences between Parkinson’s disease with dementia and dementia with Lewy bodies
- Innovative methodology to differentiate Lewy body diseases from other movement disorders
- Novel classification method on subtypes of LBD by clinical phenotypes, genetic variations, and others
- Basic research about α-synuclein as well as its synergistic effect of tau and amyloid-β underlying the mechanism in Lewy body diseases